Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ester Fonsatti

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Cardiovascular Research|October 9, 2009
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumoursEster Fonsatti, Hugues J M Nicolay, Maresa Altomonte, et al.
Annals of the New York Academy of Sciences|October 12, 2012
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyondRiccardo Danielli, Ester Fonsatti, Luana Calabrò, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 2, 2016
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal AntibodiesRiccardo Danielli, Ornella Cutaia, Carolina Fazio, et al.
Journal of Cellular Physiology|June 3, 2004
Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanomaMaresa Altomonte, Alberto Visintin, Raffaele Tecce, et al.
Journal of Cellular Physiology|December 21, 2002
Differential levels of soluble endoglin (CD105) in myeloid malignanciesLuana Calabrò, Ester Fonsatti, Giacomo Bellomo, et al.
Journal of Cellular Physiology|September 25, 2004
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implicationsLuana Calabrò, Ester Fonsatti, Maresa Altomonte, et al.
Oncoimmunology|April 9, 2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 studyCristina Maccalli, Diana Giannarelli, Filippo Capocefalo, et al.
Seminars in Oncology|October 8, 2005
Epigenetic immunomodulation of hematopoietic malignanciesValter Gattei, Ester Fonsatti, Luca Sigalotti, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2015
"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014Michele Maio, Erica Bertocci, Lorenzo Pilla, et al.
Journal of Cellular Physiology|January 25, 2002
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cellsChiara De Nardo, Ester Fonsatti, Luca Sigalotti, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Cardiovascular Research|October 9, 2009
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumoursEster Fonsatti, Hugues J M Nicolay, Maresa Altomonte, et al.
Annals of the New York Academy of Sciences|October 12, 2012
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyondRiccardo Danielli, Ester Fonsatti, Luana Calabrò, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 2, 2016
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal AntibodiesRiccardo Danielli, Ornella Cutaia, Carolina Fazio, et al.
Journal of Cellular Physiology|June 3, 2004
Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanomaMaresa Altomonte, Alberto Visintin, Raffaele Tecce, et al.
Journal of Cellular Physiology|December 21, 2002
Differential levels of soluble endoglin (CD105) in myeloid malignanciesLuana Calabrò, Ester Fonsatti, Giacomo Bellomo, et al.
Journal of Cellular Physiology|September 25, 2004
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implicationsLuana Calabrò, Ester Fonsatti, Maresa Altomonte, et al.
Oncoimmunology|April 9, 2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 studyCristina Maccalli, Diana Giannarelli, Filippo Capocefalo, et al.
Seminars in Oncology|October 8, 2005
Epigenetic immunomodulation of hematopoietic malignanciesValter Gattei, Ester Fonsatti, Luca Sigalotti, et al.
Cancer Immunology, Immunotherapy : CII|May 7, 2015
"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014Michele Maio, Erica Bertocci, Lorenzo Pilla, et al.
Journal of Cellular Physiology|January 25, 2002
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cellsChiara De Nardo, Ester Fonsatti, Luca Sigalotti, et al.
Pageof 5